Aeterna Zentaris announces $1.5M NIH award for AEZS-108 Phase 1/2 study in refractory prostate cancer Grant awarded to Dr. Jacek Pinski to conduct the study at the Norris In depth Cancer Center of the University of Southern California Aeterna Zentaris Inc comprar priligy . , , a late-stage drug development company specific in endocrine and oncology therapy, today announced that the National Institutes of Health offers awarded Dr. Jacek Pinski, Associate Professor of Medicine at the Norris Comprehensive Cancer Middle of the University of Southern California, a grant of about US$1.5 million over three years to conduct a Phase 1/2 research in refractory prostate cancer with the Company’s doxorubicin LHRH receptor targeted conjugate compound, AEZS-108.
Related StoriesNew RNA test of blood platelets may be used to identify area of cancerSausages With Antioxidants From Berries TO AVOID CancerCornell biomedical engineers develop 'super organic killer cells' to eliminate tumor cells in lymph nodesAethlon disclosed that the principal investigator of the clinical program further, which has been authorized with the Clinical Trials Registry of India, will be Vijay Kher, M.D., Chairman of the Section of Nephrology at the Medanta Kidney & Urology Institute. Dr. Furthermore to monitoring for improved acceleration of viral load decrease first of SOC, another principal endpoint will concentrate on quick viralogic response which is defined as undetectable viral load 30 days after SOC initiation.